[{"id":"c403aee5-2a23-4596-8765-c6e6713663ca","acronym":"","url":"https://clinicaltrials.gov/study/NCT05948033","created_at":"2023-07-17T14:08:48.088Z","updated_at":"2024-07-02T16:35:42.783Z","phase":"Phase 1/2","brief_title":"CD70 Targeted CAR-T Cells in CD70 Positive Relapsed/Refractory Lymphoma","source_id_and_acronym":"NCT05948033","lead_sponsor":"Chinese PLA General Hospital","biomarkers":" IL6 • TNFA • CD70 • IL2 • IL10","pipe":" | ","alterations":" CD70 expression","tags":["IL6 • TNFA • CD70 • IL2 • IL10"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD70 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • UCL70802"],"overall_status":"Recruiting","enrollment":" Enrollment 30","initiation":"Initiation: 07/15/2023","start_date":" 07/15/2023","primary_txt":" Primary completion: 12/31/2025","primary_completion_date":" 12/31/2025","study_txt":" Completion: 12/31/2026","study_completion_date":" 12/31/2026","last_update_posted":"2023-07-17"},{"id":"d6d66642-1f53-4555-8490-4700bdf032dd","acronym":"","url":"https://clinicaltrials.gov/study/NCT05947487","created_at":"2023-07-17T14:08:40.998Z","updated_at":"2024-07-02T16:35:42.879Z","phase":"Phase 1/2","brief_title":"CD70 Targeted CAR-T Cells in CD70 Positive Advanced/Metastatic Solid Tumors","source_id_and_acronym":"NCT05947487","lead_sponsor":"Chinese PLA General Hospital","biomarkers":" IL6 • TNFA • CD70 • IL2 • IL10","pipe":" | ","alterations":" CD70 expression","tags":["IL6 • TNFA • CD70 • IL2 • IL10"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD70 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e albumin-bound paclitaxel • cyclophosphamide • UCL70802"],"overall_status":"Recruiting","enrollment":" Enrollment 30","initiation":"Initiation: 07/15/2023","start_date":" 07/15/2023","primary_txt":" Primary completion: 12/31/2025","primary_completion_date":" 12/31/2025","study_txt":" Completion: 12/31/2026","study_completion_date":" 12/31/2026","last_update_posted":"2023-07-17"}]